时间：2026年9月4日
Date: Sept. 4, 2026
Novonesis豪掷6亿欧元在印度Patalganga建下一代酶制剂工厂：丹麦生物解决方案巨头加码”全球南方”供应链
Novonesis Commits €600M for a Next-Gen Enzyme Plant in Patalganga, India—Danish Bio-Solutions Giant Doubles Down on the Global South Supply Chain
摘要 :
2026年9月4日，源自Novozymes与Chr. Hansen于2024年合并成立的丹麦生物解决方案巨头Novonesis宣布：将投资6亿欧元在其位于印度Patalganga的园区新建一座下一代酶制剂生产工厂，目标于2030年前后实现全面投产。
新工厂将服务生物燃料、家清、食品饮料等30多个行业的酶制剂需求，可持续设计包括淡水回收系统与集成式热泵，目标是相较老一代工厂实质性降低Scope 1与Scope 2碳排放。由CEO Ester Baiget与首席运营官Anders Lund牵头，本次动作把印度定位为向中东与非洲外溢的”规模化枢纽”。Novonesis全球员工约1.1万人，此次Patalganga投资是公司规模最大的单一项目之一，同时兼具”分散于欧洲的产能集中风险”的供应链弹性作用。6亿欧元的投入体量、以及以2030年为目标节点的长周期时间表，意味着公司押注未来十年南亚与更广义”全球南方”的工业与消费生物科技需求将跑赢成熟市场。
Summary :
Danish biosolutions leader Novonesis, formed from the 2024 merger of Novozymes and Chr. Hansen, announced on September 4, 2026 a €600 million investment to build a next-generation enzyme production facility at its Patalganga, India site, targeting full operation by 2030.
The new plant is designed to serve enzyme demand across biofuels, household care, food & beverage and more than 30 other industries, with a sustainability envelope that includes freshwater recycling systems and integrated heat pumps aimed at cutting Scope 1 and 2 emissions materially versus a legacy footprint. President & CEO Ester Baiget and COO Anders Lund are leading the expansion, positioning India as a scale-out hub that also serves the fast-growing Middle East and Africa demand pool. Novonesis employs approximately 11,000 people globally; the Patalganga investment is one of its largest single-site capital commitments and functions as a supply-resilience move away from concentrated European production. The scale and 2030 timeline signal a long-cycle bet that industrial and consumer biotech demand from South Asia and the broader Global South will outpace mature markets across the next decade.
入选理由 :
一家丹麦生物科技巨头把6亿欧元投在印度既有园区建”第二枢纽”、且以2030年为节点——这一份新闻稿同时讲清三件事：酶制剂需求正在迁移、欧洲资本开支正在向”全球南方”重定位、以及Scope 1/2 减排路径落到具体工厂——高度集成的一条线读数。
Why Selected:
A rare €600M “second-hub” bet from a Danish biotech onto an Indian brownfield site with a 2030 horizon—one release tells the entire story of enzyme demand relocation, EU→Global-South capex migration, and Scope-1/2 decarbonization all bundled into a single line-item.
浏览量：132,600
Views：132,600
独立IP：39,000
Unique Clicks ：39,000
